BBS-Bioactive Bone Substitutes – Insider information: The company updates the status of the CE marking process
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Pressmeddelande

BBS-Bioactive Bone Substitutes – Insider information: The company updates the status of the CE marking process

BBS-Bioactive Bone Substitutes Plc | Company Release | May 05, 2024 at 21:30:00 EEST

Insider information: The company updates the status of the CE marking process

Based on the available information, the company estimates that the CE marking process will not be completed by the end of the second quarter in 2024 as previously estimated. The process is at a stage where the company has submitted the required information for product registration to the authorities.

During these final phases of the process, the company will no longer provide an exact time estimate for the completion of the CE marking process, as the company can no longer influence the processing schedules of the authorities.

The product's journey towards commercialization (updated)

PhaseActionStatus
Product developmentPreclinical animal testsCompleted

Functionality and efficiency testsCompleted

Clinical testCompleted



CE markingSubmitting the CE applicationCompleted

Quality system applicationApproved

1st auditCompleted

2nd auditCompleted

Additional auditCompleted

Additional measuresCompleted

Product approvalIn process

Product classificationCompleted

Consultation with the Medicines AgencyIn process

Production lines and line certificationIn process



CommercializationPreliminary commercializationIn process

Extensive commercializationIn preparation

Previously published announcements related to the CE marking application

  • November 25, 2023 – The Notified Body has approved the Company’s quality system
  • November 2, 2023 – Insider information: The company provides an update on the CE marking process related to the approval of the quality system – consultation with the Finnish Medicines Agency to begin on 21 November 2023
  • September 13, 2023 – Insider information: Plan to complete minor open issues approved – the Company updates its outlook on the schedule of the CE marking
  • August 31, 2023 – Inside information: The final report of the additional audit received from the Notified Body
  • May 26, 2023 – Inside information – Positive decision received on the product classification, schedule for the quality system approval to be updated
  • March 27, 2023 – Inside information: The final report of the second audit received from the Notified Body, the CE marking process may continue and CE marking approval continues to be expected during 2023
  • December 30, 2022 – Insider information: BBS updates the estimate of the CE marking approval schedule of ARTEBONE® Paste
  • November 18, 2022 – Inside information: The first audit completed by the Notified Body, CE marking process may continue as planned
  • March 9, 2022 – BBS Bioactive Bone Substitutes Plc has filed the CE-marking application of Artebone® bone void filler to the authorities

Bifogade filer

Nyheter om BBS-Bioactive Bone

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Om aktien BBS-Bioactive Bone

Senaste nytt